Myriad Genetics

Myriad Genetics, Inc. has expanded its commercial and clinical capabilities with several appointments. The company named Robert Rubens, M.D., vice president of medical affairs, and James DeMarco as vice president of sales for Myriad Pharmaceuticals, Inc. Margaret Yu, M.D., has been named director of clinical research in oncology and Andrew Beelen, M.D., as senior director of clinical research in infectious diseases.
   
Dr. Rubens will oversee education, publications, Phase IV studies, the CNS medical science team, and the medical information functions. He will lead the formulation of strategic approaches to further clinical study programs, including managing investigator-initiated clinical trials and post-marketing studies. He will also provide medical review of all promotional materials, sales training materials and medical communications. Dr. Rubens joins the company from Sepracor, where he served as executive medical director, CNS Medical Affairs and was a member of the Lunesta launch team. Prior to Sepracor, Dr. Rubens was U.S. medical director, CNS medical for Pfizer, Inc., and a member of the Relpax launch team.
   
Mr. DeMarco is responsible for establishing brand strategy to optimize sales of all commercial products and lead the U.S. and worldwide sales organizations, while overseeing functional areas of field sales, sales training and sales operations. Mr. Demarco joins the company from Idenix Pharmaceuticals, where he was vice president, U.S. Sales. His career in pharmaceutical sales began with Schering-Plough and Amgen, then Eisai and Idenix.
   
Dr. Yu is responsible for the strategic direction of clinical development plans for oncology-related compounds, including Azixa, to ensure successful registration of new drug candidates. She was previously assistant professor in the department of hematology at the University of Utah.
   
Dr. Beelen is responsible for the overall strategy and direction of clinical development in the infectious disease field, including Vivecon. Dr. Beelen joins the company from GlaxoSmithKline, where he was most recently director, clinical pharmacology and discovery medicine at their Infectious Diseases Center for Excellence in Drug Discovery.  
   
“I am pleased to extend a warm welcome to all our new employees,” said Adrian Hobden, Ph.D., president of Myriad Pharmaceuticals, Inc. “Their addition to our team greatly enhances our ability to optimize the clinical development and commercial launch of our pipeline of therapeutic products.”